BI 653048)

BI 653048) Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Products Intro: Product Name:BI 653048 phosphate
CAS:1198784-97-2
Purity:98.00% Package:100 mg;500 mg Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: HANGZHOU CLAP TECHNOLOGY CO.,LTD
Tel: 86-571-88216897,88216896 13588875226
Email: sales@hzclap.com
Products Intro: Product Name:BI 653048)
CAS:1198784-97-2
Purity:2499% Package:10kg 25kg 200 kilograms per barrel Remarks:good
Company Name: RD International Technology Co., Limited  
Tel: 18024082417
Email: market@ubiochem.com
Products Intro: Product Name:BI 653048 phosphate
CAS:1198784-97-2
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Products Intro: Product Name:BI 653048 phosphate
CAS:1198784-97-2
Package:25mg/RMB 26100
Company Name: Nanjing Shizhou Biology Technology Co.,Ltd  
Tel: 025-85560043 15850508050
Email: cindy.huang@synzest.com
Products Intro: Product Name:BI-653048
CAS:1198784-97-2
Purity:98% Package:10mg 100mg
BI 653048) Basic information
Product Name:BI 653048)
Synonyms:BI 653048);BI-653048 (BI653048;BI 653048 phosphate
CAS:1198784-97-2
MF:C23H28F4N3O8PS
MW:613.52
EINECS:
Product Categories:
Mol File:1198784-97-2.mol
BI 653048) Structure
BI 653048) Chemical Properties
Safety Information
MSDS Information
BI 653048) Usage And Synthesis
UsesBI 653048 phosphate is a selective and orally active nonsteroidalglucocorticoid (GC)agonist with an IC50 value of 55 nM[1]. BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM)[2]. BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also aHCV NS3 proteaseinhibitor that can reduce viral loads infected with thehepatitis Cvirus[3].
in vivo

BI 653048 phosphate (oral administration; 3, 10, and 30 mg/kg) at 3 mg/kg has nonsignificant decreases for all measured histology parameters (ankle inflammation, pannus formation, cartilage damage, and bone resorption), Mid-dose (10 mg/kg) treatment significantly decreases pannus and bone resorption (33%) as well as summed scores (27%), while at high dose (30 mg/kg), all parameters are significantly decreased (87–96%). The ED50 value for the summed scores is 14 mg/kg[2].

Animal Model:Mice[2]
Dosage:3, 10, and 30 mg/kg
Administration:Oral administration
Result:Exhibited significant decreases for all measured histology parameters at high doses.
IC 50CYP1A2: 50 μM (IC50); CYP2D6: 41 μM (IC50); CYP2C9: 12 μM (IC50); CYP2C19: 9 μM (IC50); CYP3A4: 8 μM (IC50)
References[1] Reeves JT, et al. Development of a large scale asymmetric synthesis of the glucocorticoid agonist BI 653048 BS H3PO4.J Org Chem. 2013 Apr 19;78(8):3616-35. DOI:10.1021/jo400079z
[2] Harcken C, et al. Optimizationofdrug-likepropertiesofnonsteroidalglucocorticoidmimeticsandidentificationof aclinicalcandidate.ACS Med Chem Lett.2014 Nov 20;5(12):1318-23. DOI:10.1021/ml500387y
[3] Montse Llinas-Brunet, et al. Latest bibliographic data on file with the International Bureau
BI 653048) Preparation Products And Raw materials
Tag:BI 653048)(1198784-97-2) Related Product Information
2-[(4R)-4-[(5-ethylsulfonyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl]-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl]-5-fluorobenzamide BI 653048) Abiraterone Budesonide Apigenin Clarithromycin